A Study Evaluating MM-310 in Patients With Solid Tumors
- First Posted Date
- 2017-03-10
- Last Posted Date
- 2018-02-27
- Lead Sponsor
- Merrimack Pharmaceuticals
- Target Recruit Count
- 34
- Registration Number
- NCT03076372
- Locations
- 🇺🇸
Duke University, Durham, North Carolina, United States
🇺🇸University California San Francisco, San Francisco, California, United States
🇺🇸Honor Health, Scottsdale, Arizona, United States
Evaluation of MM-151 + Nal-IRI + 5-FU + Leucovorin in RAS/RAF Wild-type Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-05-27
- Last Posted Date
- 2017-01-11
- Lead Sponsor
- Merrimack Pharmaceuticals
- Registration Number
- NCT02785068
Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib
- Conditions
- Interventions
- First Posted Date
- 2015-09-02
- Last Posted Date
- 2017-09-05
- Lead Sponsor
- Merrimack Pharmaceuticals
- Target Recruit Count
- 5
- Registration Number
- NCT02538627
- Locations
- 🇺🇸
Washington University, Saint Louis, Missouri, United States
🇺🇸Vanderbilt, Nashville, Tennessee, United States
🇺🇸Northside Hospital, Sandy Springs, Georgia, United States
A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-03-26
- Last Posted Date
- 2018-09-18
- Lead Sponsor
- Merrimack Pharmaceuticals
- Target Recruit Count
- 88
- Registration Number
- NCT02399137
- Locations
- 🇺🇸
Reliant Medical Group, Inc., Worcester, Massachusetts, United States
🇺🇸Banner MD Anderson Cancer Ctr., Gilbert, Arizona, United States
🇺🇸UCLA School of Medicine, Los Angeles, California, United States
MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2014-08-11
- Last Posted Date
- 2017-01-06
- Lead Sponsor
- Merrimack Pharmaceuticals
- Target Recruit Count
- 113
- Registration Number
- NCT02213744
- Locations
- 🇺🇸
Tennessee Oncology, Chattanooga, Tennessee, United States
🇺🇸Texas Oncology- Medical City, Dallas, Texas, United States
🇺🇸Magee-Womens Hospital of UPMC, Pittsburgh, Pennsylvania, United States
A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach
- Conditions
- Interventions
- First Posted Date
- 2013-01-24
- Last Posted Date
- 2017-06-22
- Lead Sponsor
- Merrimack Pharmaceuticals
- Target Recruit Count
- 84
- Registration Number
- NCT01774851
A Phase 1 Study of MM-141 in Patients With Advanced Solid Tumors
- First Posted Date
- 2012-11-26
- Last Posted Date
- 2016-08-04
- Lead Sponsor
- Merrimack Pharmaceuticals
- Target Recruit Count
- 42
- Registration Number
- NCT01733004
Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment
- First Posted Date
- 2012-01-30
- Last Posted Date
- 2018-03-21
- Lead Sponsor
- Merrimack Pharmaceuticals
- Target Recruit Count
- 112
- Registration Number
- NCT01520389
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸Horizon Oncology Research, Inc., Lafayette, Indiana, United States
🇺🇸University of Colorado Denver, Aurora, Colorado, United States
Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2011-12-19
- Last Posted Date
- 2016-06-17
- Lead Sponsor
- Merrimack Pharmaceuticals
- Target Recruit Count
- 417
- Registration Number
- NCT01494506
A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers
- First Posted Date
- 2011-10-13
- Last Posted Date
- 2016-09-08
- Lead Sponsor
- Merrimack Pharmaceuticals
- Target Recruit Count
- 48
- Registration Number
- NCT01451632